Independent directory · not a healthcare provider, pharmacy or seller Directory last updated 2026-07-28
PeptideCare Finder
Clinician-supervised care · not a healthcare provider

Clinician-supervised care · not a healthcare provider

Medical care
Find ClinicsPeptide TherapyFDA StatusCostsMedical Guides
Research suppliers — separate section
Supplier ReviewsCompare SuppliersCOA GuideTesting StandardsRegulatory Actions
Repair and regeneration peptides · Investigational as an injectable; cosmetic ingredient topically

GHK-Cu: Two Human Trials, Both Topical, Both Failed to Beat Placebo

The two randomised human trials that exist — 86 patients with leg ulcers and 13 after laser resurfacing — both failed to beat placebo on their objective endpoints, and both applied it to the skin. Not one human trial has ever injected it.

Compiled by the PeptideCare Finder editorial team · Published 2026-08-05 · Updated 2026-07-28 · Not independently reviewed by a clinician
Regulatory and anti-doping status
FDA-approved use
None, topical or injectable. Topical products are sold as cosmetics, which are not FDA-approved and may not lawfully make drug claims. No historical drug approval exists.
Classification here
Investigational as an injectable; cosmetic ingredient topically
Compounding status
Not on the 503A Bulks List. FDA lists "GHK-Cu (for injectable routes of administration)" under "bulk drug substances nominated but withdrawn" and continues to publish its risk language.
Anti-doping status
Not named on the WADA 2026 Prohibited List.

Every line above is re-verified against the primary agency source before each update. What the July 2026 FDA vote did and did not do →

What GHK-Cu is

GHK-Cu is a three-amino-acid peptide bound to a copper ion. It occurs naturally in human plasma and is thought to act as a copper carrier influencing genes involved in tissue remodelling and collagen production. It has been a cosmetic ingredient for decades.

The distinction that carries this entire page

A cosmetic ingredient with a long consumer-use history and a compounded injectable drug are not the same product. They do not share an evidence base and they do not share a safety record. Every piece of human data below concerns the topical route. No human trial of injected GHK-Cu for any purpose exists on PubMed or the trial registry — and injectable use is the version FDA lists under withdrawn nominations.

What the two human trials found

A prospective randomised evaluator-blinded trial in venous stasis ulcers with 86 evaluable patients compared a copper peptide cream, silver sulfadiazine and an inert vehicle. Silver sulfadiazine beat both the copper peptide and placebo, and there was no difference between the copper peptide and placebo. A randomised trial in 13 patients after laser resurfacing found no statistically significant difference in erythema resolution, wrinkles or skin appearance; the only endpoint that favoured GHK-Cu was subjective patient satisfaction.

A fabricated trial worth knowing about

A specific study is widely cited across supplier and supplement sites — a 67-subject split-face trial reporting a 23% reduction in wrinkle depth and a 31% increase in dermal density over twelve weeks. It does not exist in PubMed. Targeted searches return only three indexed human records for GHK-Cu, none matching. The same pages assert that randomised trials show significant improvements in skin density and photoaging scores; no such trial could be located either. An invented evidence base circulating through the seller ecosystem is itself a finding, and it is the reason this catalogue cites trials by registry number rather than by claim.

What FDA says about the injectable route

FDA’s published risk language states that compounded injectable drugs containing GHK-Cu may pose an immunogenicity risk from aggregation and peptide-related impurities, and that there are limited data in humans to inform safety considerations. For injectable GHK-Cu there is no controlled human safety data of any kind.

How far up the evidence hierarchy this reaches

Two randomised human trials exist, which is more than most substances here — but both were topical, both failed their objective endpoints, and the injectable form marketed today has never been tested in a human at all.

FDA-approved label
Adverse reactions observed in trials of known size, in a defined population.
Registered human trials This substance reaches here
Useful — but read the size. A few dozen participants cannot detect an uncommon harm.
Animal and in-vitro work
Where the literature for most marketed peptides actually sits. Not evidence of human benefit.
Testimonials and forums
Not evidence. Systematically under-reports harm.
Where a substance's best available evidence sits matters more than any claim made about it.

Where it sits on the compounding pathway

01
Nominated
Someone proposes the substance for compounding use.
02
Category 2
FDA flags significant safety risks pending evaluation.
03 Here
Nomination withdrawn
The nominator pulls it. FDA still publishes its risk language.
04
Advisory committee
A non-binding recommendation. Not a decision.
05
On the 503A Bulks List
The only stage that confers authority. Reached by rulemaking.
As of August 2026 no peptide has reached stage 05. Coverage routinely reports stage 04 as though it were stage 05.

What it is sold for, against what the evidence shows

Marketing claims on the left, in the terms sellers use. What the human literature actually supports on the right.

Marketed forWhat the evidence showsVerdict
Topical anti-wrinkle and skin appearance The one randomised facial trial, 13 patients, found no significant objective difference. Only subjective satisfaction favoured it. Contradicted
Wound healing, topical Randomised trial in 86 patients with venous ulcers: no different from placebo and inferior to silver sulfadiazine. Contradicted
Collagen synthesis and tissue remodelling Demonstrated in cell culture and animal models and mechanistically plausible; not translated into a positive human clinical endpoint. Partly supported
Injectable regeneration, anti-ageing, longevity No human trial of injected GHK-Cu exists. FDA states there are limited data in humans. No human evidence
Joint, tendon or musculoskeletal repair A 2026 sports-medicine review found no clinical data supporting musculoskeletal use. No human evidence

Where to go next

Repair and regeneration peptides
BPC-157
The other repair peptide whose reputation rests on preclinical work, and which went through the same withdrawn-nomination route.
Repair and regeneration peptides
TB-500
A closely comparable case of a marketed claim resting on research into something other than the product sold.
What this guide deliberately omits

No dosing, cycling, stacking, reconstitution or administration instructions appear anywhere on this site, and this page links to no page selling an unapproved injectable. Questions about how a substance would be used belong with a licensed clinician who has evaluated you.

Sources

  1. Bishop JB et al. A prospective randomized evaluator-blinded trial of two potential wound healing agents for venous stasis ulcers. J Vasc Surg, 1992
  2. Effects of topical copper tripeptide complex on CO2 laser-resurfaced skin. Arch Facial Plast Surg, 2006
  3. Mayfield CK et al. Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. Am J Sports Med, 2026
  4. FDA — Certain bulk drug substances that may present significant safety risks